Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD

114.48  -4.24 (-3.57%)

After market: 114.48 0 (0%)

Fundamental Rating

7

NBIX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes NBIX very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

NBIX had positive earnings in the past year.
NBIX had a positive operating cash flow in the past year.
Each year in the past 5 years NBIX has been profitable.
Each year in the past 5 years NBIX had a positive operating cash flow.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

NBIX has a Return On Assets of 9.18%. This is amongst the best in the industry. NBIX outperforms 96.07% of its industry peers.
The Return On Equity of NBIX (13.18%) is better than 95.89% of its industry peers.
NBIX has a better Return On Invested Capital (13.20%) than 96.43% of its industry peers.
NBIX had an Average Return On Invested Capital over the past 3 years of 11.40%. This is below the industry average of 14.23%.
The last Return On Invested Capital (13.20%) for NBIX is above the 3 year average (11.40%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.18%
ROE 13.18%
ROIC 13.2%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

NBIX's Profit Margin of 14.49% is amongst the best of the industry. NBIX outperforms 95.89% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
NBIX has a better Operating Margin (24.75%) than 96.79% of its industry peers.
In the last couple of years the Operating Margin of NBIX has declined.
The Gross Margin of NBIX (98.56%) is better than 98.04% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.75%
PM (TTM) 14.49%
GM 98.56%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 7.84 indicates that NBIX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.84, NBIX belongs to the top of the industry, outperforming 85.89% of the companies in the same industry.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.84
ROIC/WACC1.42
WACC9.29%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 3.40 indicates that NBIX has no problem at all paying its short term obligations.
The Current ratio of NBIX (3.40) is worse than 60.18% of its industry peers.
A Quick Ratio of 3.28 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a Quick ratio of 3.28. This is in the lower half of the industry: NBIX underperforms 60.18% of its industry peers.
Industry RankSector Rank
Current Ratio 3.4
Quick Ratio 3.28
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.95% over the past year.
Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 58.39% on average per year.
Looking at the last year, NBIX shows a very strong growth in Revenue. The Revenue has grown by 24.81%.
NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.48% yearly.
EPS 1Y (TTM)35.95%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-30.56%
Revenue 1Y (TTM)24.81%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%21.84%

3.2 Future

NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.25% yearly.
Based on estimates for the next years, NBIX will show a quite strong growth in Revenue. The Revenue will grow by 13.54% on average per year.
EPS Next Y35.66%
EPS Next 2Y41.99%
EPS Next 3Y40.83%
EPS Next 5Y41.25%
Revenue Next Year14.22%
Revenue Next 2Y15.55%
Revenue Next 3Y15.05%
Revenue Next 5Y13.54%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15 20

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 34.80, which means the current valuation is very expensive for NBIX.
NBIX's Price/Earnings ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.64% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.98. NBIX is around the same levels.
With a Price/Forward Earnings ratio of 25.65, NBIX can be considered very expensive at the moment.
NBIX's Price/Forward Earnings ratio is rather cheap when compared to the industry. NBIX is cheaper than 92.86% of the companies in the same industry.
NBIX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.66.
Industry RankSector Rank
PE 34.8
Fwd PE 25.65
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

96.61% of the companies in the same industry are more expensive than NBIX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, NBIX is valued cheaply inside the industry as 96.07% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.48
EV/EBITDA 14.87
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NBIX may justify a higher PE ratio.
NBIX's earnings are expected to grow with 40.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.98
PEG (5Y)0.6
EPS Next 2Y41.99%
EPS Next 3Y40.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NBIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (3/3/2025, 4:10:15 PM)

After market: 114.48 0 (0%)

114.48

-4.24 (-3.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06 2025-02-06/amc
Earnings (Next)04-29 2025-04-29/bmo
Inst Owners96.99%
Inst Owner Change2.07%
Ins Owners1%
Ins Owner Change1.64%
Market Cap11.41B
Analysts83.75
Price Target169.5 (48.06%)
Short Float %2.45%
Short Ratio2.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.27%
Min EPS beat(2)-37.18%
Max EPS beat(2)-17.35%
EPS beat(4)0
Avg EPS beat(4)-38.78%
Min EPS beat(4)-59.17%
Max EPS beat(4)-17.35%
EPS beat(8)2
Avg EPS beat(8)-103.25%
EPS beat(12)2
Avg EPS beat(12)-88.07%
EPS beat(16)3
Avg EPS beat(16)-76.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.31%
Min Revenue beat(2)-2.16%
Max Revenue beat(2)1.54%
Revenue beat(4)2
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)5.99%
Revenue beat(8)4
Avg Revenue beat(8)0.67%
Revenue beat(12)7
Avg Revenue beat(12)1.15%
Revenue beat(16)8
Avg Revenue beat(16)0.23%
PT rev (1m)-0.78%
PT rev (3m)1.9%
EPS NQ rev (1m)-34.48%
EPS NQ rev (3m)-32.64%
EPS NY rev (1m)-30.14%
EPS NY rev (3m)-27.13%
Revenue NQ rev (1m)-2.81%
Revenue NQ rev (3m)-3.16%
Revenue NY rev (1m)-3.22%
Revenue NY rev (3m)-2.04%
Valuation
Industry RankSector Rank
PE 34.8
Fwd PE 25.65
P/S 4.85
P/FCF 20.48
P/OCF 19.17
P/B 4.41
P/tB 4.47
EV/EBITDA 14.87
EPS(TTM)3.29
EY2.87%
EPS(NY)4.46
Fwd EY3.9%
FCF(TTM)5.59
FCFY4.88%
OCF(TTM)5.97
OCFY5.22%
SpS23.62
BVpS25.97
TBVpS25.61
PEG (NY)0.98
PEG (5Y)0.6
Profitability
Industry RankSector Rank
ROA 9.18%
ROE 13.18%
ROCE 18.16%
ROIC 13.2%
ROICexc 32.81%
ROICexgc 33.77%
OM 24.75%
PM (TTM) 14.49%
GM 98.56%
FCFM 23.66%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexcg growth 3Y35.59%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score9
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 140.96%
Cap/Sales 1.62%
Interest Coverage 364.38
Cash Conversion 97.59%
Profit Quality 163.26%
Current Ratio 3.4
Quick Ratio 3.28
Altman-Z 7.84
F-Score9
WACC9.29%
ROIC/WACC1.42
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)35.95%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-30.56%
EPS Next Y35.66%
EPS Next 2Y41.99%
EPS Next 3Y40.83%
EPS Next 5Y41.25%
Revenue 1Y (TTM)24.81%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%21.84%
Revenue Next Year14.22%
Revenue Next 2Y15.55%
Revenue Next 3Y15.05%
Revenue Next 5Y13.54%
EBIT growth 1Y47.67%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year31.86%
EBIT Next 3Y30.06%
EBIT Next 5Y29.42%
FCF growth 1Y54.09%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y52.71%
OCF growth 3Y32.41%
OCF growth 5Y31.38%